Figure 6. PD-1 and CTLA-4 combination blockade decreases CD11b⁺F4/80⁺ macrophages, CD11b⁺Ly6C^medLy6G⁺ G-MDSCs, and regulatory CD11b⁺ DCs in TSC2-deficient tumors.

Mice carrying TSC2-deficient 105K tumors were treated as illustrated in Figure 2A. Tumor-infiltrating lymphocytes (TILs) were isolated and stained for myeloid lineage and activation markers. Percentage of CD11b⁺F4/80⁺ macrophages and CD80⁺CD86⁺ macrophages (A), CD11b⁺Ly6C^medLy6G⁺ G-MDSCs and CD11b⁺Ly6C⁺Ly6G^– M-MDSCs (B), CD11c⁺CD11b^– DCs and CD11c⁺CD11b⁺ DCs (C), and NK cells (D) within CD45⁺ cells isolated from TSC2-deficient 105K tumors are shown (n = 6–8 per group). Data are presented as mean ± SD. Statistical significance was determined by nonparametric 1-way ANOVA followed by Dunn’s multiple comparison test. *P < 0.05.